Thanks, Lukas, and good day everybody. Thanks for joining us. We're continuing to see traction in operational recovery. Occupancy in our skilled nursing portfolio has now improved every month in the fourth quarter and continued through January. Occupancy October through January in our skilled nursing portfolio improved to 130 basis points. Our skilled mix jumped up dramatically in the first quarter as well. Labor trends are improving, but it's still tough, and it's going to be a bit of a slog there I think for a while, but we're certainly off our highs in terms of inflationary increases and agency utilization. So, we feel good about the progress has been made there as well. EBITDARM coverage without PRF and that's really the only way we think everyone should be looking at it at this point has improved sequentially on a trailing 12-month basis and even more so on a trailing three-month basis. I want to comment on a couple of specific operators. I think everybody saw I noted Signature Health coverage declined. Signature Health had a tough second half. They sold 24 facilities close to and right-sized their corporate infrastructure to accommodate a leaner company. And so that was quite distracting for them. However, their first quarter rebounded dramatically and I went back over a year and a half to find a quarter that was as strong as the first quarter is for Signature Health and wasn't able to find one. So we feel really good about where Sig Health is on a current basis. Similarly, Avamere, while their coverage was fine as reported. They also had a strong first quarter as well. Comment quickly on the transition from the old North American portfolio, that's going well for Avamere and it's going well for Ensign, as Ensign noted on their earnings call, they are ahead of schedule even though there's still a lot of upside to be had there. So in terms of our three largest operators, Sig Health and Avamere and Ensign, we feel like we're in a really good place with all three of those operators right now. We're pleased with the proposed 3.7% market basket and we do expect better than historical Medicaid rate increases. Most of those rate increases for our portfolio will be effective on July 1st. We'll have some more clarity probably over the next several weeks on what those rates will be. Our expectation, though, is that some states will be extending COVID rate add-ons and some will update the cost report base year to reflect more current data and that's a reflection of the fact that many states do acknowledge the impact of COVID on the industry and the lack of viability of some of the Medicaid rate increases in certain states. So as we saw last summer, we're seeing some of the same things this summer, and states are being more generous with their Medicaid rates. Investment activity is light and will remain so in the near-term. Competitive landscape has changed with lender loans and liquidity needs driving sales. Pricing uncertainty exists and I'm sure Talya will talk more about that as well. On Enlivant, as noted in the press release, we have terminated our position in the JV. There was no impact on earnings or any other ramifications to the company other than the fact that there are a number of folks out there, rating agencies, and others who still look at the debt carried by the JV. And so that obviously is gone. So from that perspective, for those that looked at the JV that it's a delevering event for us. We're now focused on transitioning the 11 wholly-owned facilities to new operator. I would note on the 11 wholly owned facilities, they are different than the JV portfolio. The JV portfolio was part of the original ALC acquisition. The 11 facilities that we own came afterwards. And these are large facilities and larger markets that are primarily a combination of AL and memory care patients or residents. And with that I will turn the call over to Talya.